Cefoperazone Sodium for Injection

Cefoperazone is a third-generation cephalosporin. It has good antibacterial effects on Escherichia coli, Klebsiella, Proteus, Salmonella typhi, Shigella, Citrobacter and other Enterobacteriaceae and Pseudomonas aeruginosa, but has poor effects on Enterobacter aerogenes, Enterobacter cloacae, Salmonella typhimurium and Acinetobacter. Influenzae, Neisseria gonorrhoeae and Neisseria meningitidis are highly sensitive to this product. This product also has a good effect on all groups of streptococci and pneumococci, and has only a moderate effect on Staphylococcus aureus (methicillin-sensitive strains), and Enterococci are resistant. Cefoperazone has a good effect on most Gram-positive anaerobes and some Gram-negative anaerobes, and Bacteroides fragilis is resistant to this product. Cefoperazone has poor stability against most β-lactamases. This product mainly inhibits the synthesis of bacterial cell walls.

The main ingredient of this product is cefoperazone sodium, and its chemical name is: (6R,7R)-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-7-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarbonylamino)-2-p-hydroxyphenyl-acetylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate sodium.

This product is a white crystalline powder, easily soluble in water, with a pH of 5.0-6.5 for a 25% aqueous solution, and the color of the solution is colorless to light yellow depending on the concentration. This product contains 34 mg of sodium per gram (1.5 milliequivalents). Each bottle contains 0.5 g, 1 g, and 2 g of cefoperazone sodium (calculated as cefoperazone).

It is suitable for various infections caused by sensitive bacteria such as pneumonia and other lower respiratory tract infections, urinary tract infections, biliary tract infections, skin and soft tissue infections, sepsis, peritonitis, pelvic infections, etc. The latter two should be used in combination with anti-anaerobic drugs.

It can be used for intramuscular injection, intravenous injection or intravenous drip. Common dosage for adults: for general infection, 1-2g once, once every 12 hours; for severe infection, 2-3g once, once every 8 hours. For patients receiving hemodialysis, one dose should be supplemented after dialysis. The daily dose for adults does not exceed 9g, but when immunodeficient patients have severe infections, the dose can be increased to 12g per day. Common dosage for children: 50-200mg/kg per day, divided into 2-3 intravenous drips. To prepare intramuscular injection, add 2.8ml of sterile water for injection and 1ml of 2% lidocaine injection for every 1g of drug, and the concentration is 250mg/ml. For intravenous slow injection, add 40ml of glucose and sodium chloride injection for every 1g of drug to dissolve; for intravenous drip, take 1-2g of cefoperazone and dissolve it in 100-200ml of glucose and sodium chloride injection or other diluents, and the final drug concentration is 5-25mg/ml. The sodium content of each 1g of cefoperazone is 1.5mmol (34mg).

1. Skin rash is more common, reaching 2.3% or more. 2. A small number of patients may also experience diarrhea, abdominal pain, eosinophilia, and mild neutropenia. 3. Temporary increase in serum aminotransferase, alkaline phosphatase, urea nitrogen or blood creatinine. 4. Thrombocytopenia, prolonged prothrombin time, etc. can be seen in individual cases. Occasional bleeding can be prevented or controlled with vitamin K. 5. Dysbacteriosis may occur in a small number of patients. 6. Those who drink alcohol or take alcoholic drugs or beverages during the use of this product may experience a disulfiram-like reaction.

This product is contraindicated in patients with known allergy to cephalosporin antibiotics.

1. This product has a synergistic effect on certain sensitive strains of Enterobacteriaceae and Pseudomonas aeruginosa when used in combination with aminoglycoside antibiotics (gentamicin and tobramycin). 2. This product can produce hypoprothrombinemia and thrombocytopenia. When used simultaneously with the following drugs, it may cause bleeding: anticoagulant heparin, coumarin or indandione derivatives, thrombolytic drugs, non-steroidal anti-inflammatory analgesics (especially aspirin, diflunisal or other salicylic acid preparations) and sulfinpyrazone, etc. 3. This product contains a methylthiotetrazolyl side chain in its chemical structure. Therefore, drinking alcohol or intravenous injection of ethanol-containing drugs during the use of this product will inhibit the activity of acetaldehyde dehydrogenase, causing acetaldehyde accumulation in the blood, and causing disulfiram-like reactions such as drowsiness and hallucinations. Therefore, during the medication period and within 5 days after stopping the medication, patients cannot drink alcohol, take oral or intravenous injection of ethanol-containing drugs. 4. This product cannot be infused in the same bottle when used in combination with aminoglycoside antibiotics, because they may affect each other's antibacterial activity. 5 This product is contraindicated with the following drug injections: amikacin, gentamicin, kanamycin B, doxycycline, meclofenoxate, amarin (Bianmailing), diphenhydramine, potassium magnesium aspartate, hydroxyzine hydrochloride (Antalol), procainamide, aminophylline, prochlorperazine, cytochrome C, pentazocine (Zhentongxin), aprotinin, etc.

Sealed and stored below 25°C. Valid for 3 years (below 5°C).

1.0g (calculated as C25H27N9O8S2)

Viatris Pharmaceuticals (DALIAN) Co., Ltd.

• Founded in:

  1989-10-07

• Address:

  No. 22 Daqing Road, Dalian Economic and Technological Development Zone, Liaoning Province

• Tax NO.:

  912102006048147187

• Registered Funds:

  $80.4 million

• Website:

  Log in to view

• Email:

  Log in to view